<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161908">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990782</url>
  </required_header>
  <id_info>
    <org_study_id>08-634</org_study_id>
    <nct_id>NCT00990782</nct_id>
  </id_info>
  <brief_title>Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment</brief_title>
  <acronym>CEPELA</acronym>
  <official_title>CEPELA I Trial: Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Given Imaging Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study utilizes a disposable capsule endoscope (Pillcam ESO) to assess the condition of
      a patient's esophagus before and after the RFA procedure, as the injury rate to the
      esophagus has not been established.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing radiofrequency ablation (RFA) therapy for atrial fibrillation, can
      sometimes experience insult or injury to the esophagus, due to the proximity of the
      esophagus to the RFA treatment area. This study utilizes a disposable capsule endoscope
      (Pillcam ESO) to assess the condition of a patient's esophagus before and after the RFA
      procedure, as the injury rate to the esophagus has not been established.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>capability of the PillCam ESO 2 capsule endoscope to identify esophageal injury due to RFA therapy for atrial fibrillation</measure>
    <time_frame>24-48 hrs post RFA, and 14 days post-RFA</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>compare patient post-ablation symptoms to esophageal injury findings identified by PillCam ESO capsule endoscope</measure>
    <time_frame>24-48 hrs post-RFA and 14 days post-RFA</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Esophageal Lesion</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PillCam ESO Capsule Endoscope - all patients receive capsule endoscopy before and after RFA procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PillCam ESO Capsule Endoscope</intervention_name>
    <description>Utilization of the PillCam ESO capsule endoscope to evaluate the condition of a patient's esophagus before and after RFA therapy to treat atrial fibrillation.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic patients with persistent atrial fibrillation selected for radiofrequency
             ablation

          -  Adults aged 18 years and older

          -  Patients able to give informed consent

        Exclusion Criteria:

          -  Patients under the age of 18

          -  Patient unable to or unwilling to swallow the capsule endoscopes

          -  Patients with cardiac pacemakers, implanted cardiac defibrillators or other implanted
             electro-medical devices

          -  Pregnant or lactating females

          -  Subjects with history of abdominal, pelvic, or bowel surgery within the past year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milan Dodig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>October 6, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
